Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Colonic Disease Clear all
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Drug · Combination Product
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 10:18 AM EDT
Not yet recruiting Early Phase 1 Interventional

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT07238790
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Diarrhea
Interventions
MITI-001 administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pregabalin and Colonic Function

NCT01094808
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Dublin, California • Fremont, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Contribution of Pain and Inflammation in IBS

NCT01436760
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional Results available

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

NCT01471379
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Spencer Dorn, MD, MPH
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional Results available

Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data

NCT00880256
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
mindfulness-based stress reduction
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational

Development of a Questionnaire to Measure Hypervigilance for Visceral Pain

NCT01166802
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational

LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01257477
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jul 22, 2026, 10:18 AM EDT
Not listed Phase 2Phase 3 Interventional

Probiotic (Visbiome) for Gulf War Illness

NCT03078530
View directory record Official record
Conditions
Gulf War Illness
Interventions
Placebo, Visbiome, VSL#3
Drug
Lead sponsor
Ashok Tuteja
Federal
Eligibility
35 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy

NCT01413945
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 22, 2026, 10:18 AM EDT
Not listed Not applicable Interventional

Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

NCT00985400
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Exercise Program, Telephone-based intervention, Counseling intervention, Questionnaire administration, Relaxation Program
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional

Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms

NCT03035799
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paleolithic diet, General Healthful Diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional

Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain

NCT06653647
View directory record Official record
Conditions
Functional Abdominal Pain Disorders, Irritable Bowel Syndrome (IBS), Functional Gastrointestinal Disorders, Functional Colonic Disease, Gastrointestinal Disease, Digestive System Diseases, Neurological Manifestations, Signs and Symptoms, Digestive, Pain, Abdominal Pain/ Discomfort
Interventions
Guided Imagery Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cheno Effect on Transit in Health and IBS-C

NCT00912301
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Sodium chenodeoxycholate (NaCDC), Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

NCT00810329
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Multiple Chemical Sensitivity, Interstitial Cystitis, Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Jul 22, 2026, 10:18 AM EDT
Not listed Not applicable Interventional

Effect of Diet on Gulf War Illness

NCT02881944
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Low FODMAP Diet, High FODMAP Diet
Behavioral
Lead sponsor
Ashok Tuteja
Federal
Eligibility
25 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

NCT05470387
View directory record Official record
Conditions
Ileus, Gastro-Intestinal Disorder
Interventions
LB1148, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Mobile, Alabama • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jul 22, 2026, 10:18 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cerebral Cortical Influences on Autonomic Function

NCT03869372
View directory record Official record
Conditions
Healthy Subjects, Functional Dyspepsia, Irritable Bowel Syndrome
Interventions
rTMS
Device
Lead sponsor
David Levinthal
Other
Eligibility
21 Years to 60 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

NCT01414244
View directory record Official record
Conditions
Diarrhea-Predominant Irritable Bowel Syndrome
Interventions
Glutamine
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 72 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jul 22, 2026, 10:18 AM EDT